Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change
19/06/26	0.3810 €	-2.43%
18/06/26	0.3905 €	+6.26%
17/06/26	0.3675 €	0.00%
16/06/26	0.3675 €	+0.41%
15/06/26	0.3660 €	+7.02%

Real-time BOERSE MUENCHEN

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3860EUR

Average target price

1.000EUR

Spread / Average Target

+159.07%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - BOERSE MUENCHEN Other stock markets 23:43:24 19/06/2026 +03			5-day change	1st Jan Change
0.3810 ^EUR	-2.43%		+13.02%	+31.26%

06-18	Nicox Receives Positive Feedback from China
06-18	Nicox Announces Positive Pre-Submission Regulatory Feedback in China Supporting NDA Filing for NCX 470	CI

Market Cap	34.02M 39.02M 31.51M 29.49M 55.31M 3.68B 55.65M 374M 145M 1.81B 146M 143M 6.29B	P/E 2026 *	38.6x	P/E 2027 *	3.22x
Enterprise Value	34.02M 39.02M 31.51M 29.49M 55.31M 3.68B 55.65M 374M 145M 1.81B 146M 143M 6.29B	EV / Sales 2026 *	3.4x	EV / Sales 2027 *	1.7x
Free-Float	99.65%	Yield 2026 *	-	Yield 2027 *	-

06-18	Nicox Receives Positive Feedback from China
06-18	Nicox Announces Positive Pre-Submission Regulatory Feedback in China Supporting NDA Filing for NCX 470	CI
04-30	Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-24	Nicox SA Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting	CI
02-24	Edenred, Forvia, Freelance.com... Key Stocks to Watch Today in Paris -
02-24	Nicox Reports Positive Phase 3 Results for NCX 470
02-16	Nicox, Sanofi, Valneva... Stocks to Watch Today in Paris
02-16	Nicox Moves Forward with U.S. Health Authorities for Its NCX 470
01-05	Nicox Strengthens Its Financial Position
01-05	Exail, Alstom, Equasens... Stocks to Watch Today in Paris
01-05	Nicox Repays Debts to Kreos Capital, Extends Cash Runway	MT
01-05	Nicox: To Watch Today
01-05	Nicox Repays Debt with Kreos Capital and Extends Its Financing Horizon

06-18	Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470	GL
06-08	Reminder: Nicox June 2024 Warrants will expire June 19, 2026	GL
06-03	Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative	GL
04-30	Nicox Provides Full Year 2025 Financial Results and Corporate Update	GL
04-20	Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026	GL

Nicox SA Stock BOERSE MUENCHEN

Stocks

NXOA

FR0013018124

Pharmaceuticals

Valuation: Nicox SA

Chart: Nicox SA

Latest news : Nicox SA

Press Releases: Nicox SA

News in other languages: Nicox SA

Quotes and Performance

Course Extremes

Managers and Directors: Nicox SA

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

06-19	Agenda des dividendes et des AG de la semaine : session dividendes pour la galaxie Bolloré
06-18	Bourse : L'Oréal met le cap sur l'Inde, gros contrat pour Alstom, rumeur sur Edenred
06-18	Nicox reçoit des retours positifs de la Chine
06-18	Star Warsh
06-18	Nicox annonce des retours réglementaires préalables positifs en Chine soutenant le dépôt du NDA pour NCX 470

1 week	+11.40%
Current month	-1.68%
1 month	-2.31%
3 months	-8.08%
6 months	+34.39%
Current year	+28.07%

Manager	Title	Age	Since
Gavin Spencer CEO	Chief Executive Officer	55	28/02/2024
Sandrine Gestin DFI	Director of Finance/CFO	58	01/01/2015
Doug Hubatsch CTO	Chief Tech/Sci/R&D Officer	-	13/12/2021

Director	Title	Age	Since
Gavin Spencer BRD	Director/Board Member	55	08/04/2024
Damian Marron CHM	Chairman	64	16/07/2024
Marc Bozec BRD	Director/Board Member	-	16/07/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NICOX SA	-2.43%	+13.02%	+70.09%	-27.29%	39.02M
MERCK & CO., INC.	-1.36%	-4.35%	+44.03%	+3.30%	281B
MERCK KGAA	-0.11%	-0.26%	+20.49%	-14.40%	66.27B
KYOWA KIRIN CO., LTD.	+1.30%	+5.71%	+2.24%	-7.88%	8.24B
HALOZYME THERAPEUTICS, INC.	-0.03%	-1.37%	+29.80%	+98.29%	8.13B
SK BIOPHARMACEUTICALS CO., LTD.	-1.92%	-1.02%	-6.35%	+4.44%	4.45B
YUHAN CORPORATION	-2.69%	-1.42%	-26.97%	+36.12%	3.71B
BETTA PHARMACEUTICALS CO., LTD.	+8.33%	+2.08%	+0.22%	+12.14%	3.42B
SUPERNUS PHARMACEUTICALS, INC.	+1.84%	-0.07%	+37.48%	+32.32%	2.58B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-1.01%	-2.64%	+5.02%	-26.66%	1.92B
Average	+0.48%	-1.51%	+17.61%	+11.04%	42.22B
Weighted average by Cap.	-0.96%	-4.30%	+36.80%	+2.46%

	2026 *	2027 *
Net sales	10M 11.47M 9.26M 8.67M 16.26M 1.08B 16.36M 110M 42.58M 533M 43.05M 42.13M 1.85B	20M 22.94M 18.52M 17.34M 32.52M 2.16B 32.72M 220M 85.16M 1.07B 86.1M 84.26M 3.7B
Net income	1M 1.15M 926K 867K 1.63M 108M 1.64M 10.99M 4.26M 53.27M 4.31M 4.21M 185M	11M 12.62M 10.19M 9.54M 17.89M 1.19B 17.99M 121M 46.84M 586M 47.36M 46.34M 2.03B
Net Debt	-	-

1 week	0.34	0.4
1 month	0.33	0.4
3 years	0.15	0.65
5 years	0.15	4